Estimating the Length of the Preclinical Detectable Phase for Open-Angle Glaucoma.

ABSTRACT:

Importance

A 50% reduction of glaucoma-related blindness has previously been demonstrated in a population that was screened for open-angle glaucoma. Ongoing screening trials of high-risk populations and forthcoming low-cost screening methods suggest that such screening may become more common in the future. One would then need to estimate a key component of the natural history of chronic disease, the mean preclinical detectable phase (PCDP). Knowledge of the PCDP is essential for the planning and early evaluation of screening programs and has been estimated for several types of cancer that are screened for.

Objective

To estimate the mean PCDP for open-angle glaucoma.

Design, setting, and participants

A large population-based screening for open-angle glaucoma was conduc

SUBMITTER: Aspberg J 

PROVIDER: S-EPMC9857634 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature